Novo Seeds co-led a $61.7m round for the oncology therapy developer with Ysios Capital, following a Novo Nordisk Foundation grant.

Denmark-based antibody drug conjugate (ADC) developer Adcendo completed a €51m ($61.7m) series A round yesterday co-led by pharmaceutical firm Novo through its Novo Seeds subsidiary. Venture capital firm Ysios Capital co-led the round, which also featured investment management firm RA Capital Management, VC firm HealthCap and healthcare investment firm Gilde Healthcare. Adcendo is developing ADCs…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.